Medicago Inc.
http://www.medicago.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medicago Inc.
Harvest Time? Medicago And GSK Expect Summer Readout For Plant-Based COVID Vaccine
Medicago’s vaccine has generated a strong immune responses in a Phase II trial, which could see it finally reap the benefits of its plant-based technology.
Coronavirus Update: Takeda Contractor To Manufacture J&J Vaccine; Moderna Starts Pediatric Trial
Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.
Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
Allergy Therapeutics Takes First Steps Into Broader Vaccine Field
Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.
Company Information
- Industry
- Biotechnology
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies